Botensilimab - Agenus
Alternative Names: AGEN-1181; Anti-CTLA-4 Monoclonal Antibody AGEN1181; BOT - Agenus; Fc-enhanced CTLA-4 antibodyLatest Information Update: 05 Feb 2025
Price :
$50 *
At a glance
- Originator Agenus
- Developer Agenus; Immune Oncology Research Institute
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Solid tumours
- Phase II Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma
Most Recent Events
- 30 Jan 2025 Updated efficacy and safety data from a phase-I/II trial in Solid tumours released by Agenus
- 22 Jan 2025 Efficacy and adverse events data from the phase I/II trial in adenocarcinoma trial in Adenocarcinoma released by Agenus
- 22 Jan 2025 Efficacy and adverse events data from the phase II UNICORN trial in Adenocarcinoma released by Agenus